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ABSTRACT 
 
CD4+ T cells play a key role in orchestrating an efficient immune response to viral infection; 
yet due to a variety of factors remain relatively poorly studied. However, recent 
advancements in MHC class II tetramer technology are allowing single cell analysis of CD4+ 
T cell responses to be studied for the first time. We sought to take advantage of these 
reagents in the context of the oncogenic herpesvirus EBV, in order to establish the cytokine 
profiles and cytotoxic potential of CD4+ T cells specific for a variety of viral epitopes. Such 
knowledge would help with the improvement of adoptive T cell therapies for EBV-related 
malignancies that have been shown to be more efficacious with higher proportions of CD4+ T 
cells. 
Using flow cytometry we found that the EBV-specific CD4+ T cells are capable of responding 
to EBV-infected cells ex vivo. Using MHC class II tetramers we have demonstrated that 
responding cells were a heterogeneous population expressing the Th1 associated 
transcription factor T-bet and were polyfunctional producing IFNγ, TNFα or a combination of 
both. In addition we found that unmanipulated CD4+ T cells specific for EBV-derived epitopes 
possess cytotoxic potential ex vivo.  
These results may help to improve immune therapy for EBV-associated cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS  
 
I would first and foremost like to thank my supervisor Dr Heather Long for her help and 
guidance throughout this project. Her willingness to assist me in the lab, during data analysis 
and whilst writing up have been invaluable. 
I would also like to thank Gordon Ryan for helping me during my time in the T cell laboratory. 
In addition, I am very grateful for the support and advice given by Calum Forest, Alison 
Leese, Luke Williams and Jill Brookes. 
Finally, all of the experiments performed would not have been possible if it were not for the 
members of the school of cancer sciences who so generously donate blood. I am extremely 
grateful for their availability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
1. INTRODUCTION 
 
1.1   Epstein-Barr virus        p.1 
1.2   T cell response to EBV       p.2 
1.3   EBV associated malignancies and immunotherapy    p.3 
1.4   CD4+ T cells in immunity and infection     p.5 
1.5   Therapeutic use of CD4+ T cells      p.10 
1.6   Aims          p.12 
2. MATERIALS AND METHODS 
 
2.1  Ethic statements and donors       p.13 
2.2 Cell preparations        p.13 
2.3 Lymphoblastoid cell line (LCL) generation     p.13 
2.4  Intracellular cytokine staining following staphylococcus enterotoxin B (SEB) or 
LCL stimulation or EBV peptide stimulation     p.14 
2.5 EBV MHC class II tetramer staining      p.15 
2.6 Combination of MHC II Tetramer and intracellular cytokine staining following 
peptide stimulation        p.15 
2.7  EBV specific CD4+ T cell phenotyping     p.16 
3. RESULTS 
 
3.1 Optimisation of antibody panels for CD4+ T cell phenotype and function    
identification         p.17 
 3.2   Lineage and cytokine profile of EBV specific CD4+ T cells   p.22 
3.3  Frequency of CD4+ EBV epitope MHC class II tetramer responses in healthy 
seropositive individuals       p.30 
3.4  Lineage and cytokine profile of EBV epitope specific CD4+T cells in healthy 
seropositive individuals       p.33 
3.5 Cytotoxic potential and phenotype of EBV epitope specific CD4+ memory T        
cell population         p.40 
 
4. DISCUSSION          p.45 
 
5. REFERENCES          p.52 
LIST OF FIGURES 
 
 
Figure 1.1 CD4+ T cell central to immune response to viral infection   p.5 
Figure 1.2 CD4+ T cell subsets        p.8 
Figure 1.3 CD4+ T cell memory phenotype and cytotoxic potential    p.10 
 
Figure 3.1 Gating strategy and antibody titration      p.20 
Figure 3.2 CD4+ T cell response to autologous LCL stimulation    p.28 
Figure 3.3 Tetramer responses in healthy EBV seropositive donors    p.32 
Figure 3.4 Intracellular staining of PRS tetramer positive CD4+ T cells following EBV peptide 
stimulation           p.37 
Figure 3.5 Cytotoxic potential and phenotype of EBV MHC II tetramer specific CD4 
populations           p.43 
 
 
LIST OF TABLES 
Table 1. MHC II tetramer reagents        p.16 
 
 
 
1 
 
1. INTRODUCTION 
 
1.1 Epstein-Barr virus 
The Epstein Barr virus (EBV) is an oncogenic human gammaherpesvirus that is widespread 
throughout the world.  Infection is usually asymptomatic if it occurs during childhood, 
however seroconversion can cause a self-limiting illness, infectious mononucleosis in 
adolescence, characterised by fever and malaise. Thereafter, in the majority of 
immunocompetent individuals, the virus persists for life, largely asymptomatically, as it is 
kept under control by the host’s T cell immune system. 
Virus transfer occurs orally through saliva and while EBV is B cell tropic, it is also capable of 
infecting epithelial cells and in rare cases T and natural killer cells. The early stages of 
infection are not well understood but involve lytic effect of permissive cells in the oropharynx. 
However, once the virus has passed through the epithelial layer, infection of locally infiltrating 
B cells has been well described and occurs through the respective interaction between the 
viral glycoproteins gp350 and gp42 with CD21 and MHC class II present on B lymphocytes 
(Young, Rickinson, 2004). 
During this time, EBV establishes a latent growth-transforming infection in B cells by 
expressing a set of ten latent proteins comprised of six EBV nuclear antigens (EBNAs 1, 2, 
3A, 3B, 3C and –LP), three latent membrane proteins (LMPs 1, 2A and 2B) and BHRF1 
(Young, Rickinson, 2004; Kelly et al., 2009). The EBV lytic and latent proteins are highly 
immunogenic to the immune system and primary infection is eventually brought under control 
by a strong T cell response. Some EBV infected B cells down regulate gene expression to 
avoid T cell destruction and thus a reservoir of genome positive but antigen negative B cells 
is established. The periodic reactivation of such cells coupled with newly infected B cells 
maintains this population throughout the life of the host. 
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1.2 T cell response to EBV 
In the case of EBV, the identifiable clinical syndrome of infectious mononucleosis has 
enabled researchers to study the immune response to primary infection and to follow patients 
through recovery and into asymptomatic carriers of EBV.  Thus, this is a particularly good 
model to study the immune response to viruses. The initial response is characterised by a 
large expansion of EBV-specific CD8+ T cells and as a result, the CD8+ T cell response has 
been well studied. With the use of MHC class I tetramer staining, it has been shown that this 
response is skewed towards proteins from the immediate early (IE) and early (E) phases of 
the lytic virus replication cycle (Pudney et al., 2005, Abbott et al., 2013). Responses to single 
epitopes derived from lytic proteins can account for up to 40% of the total CD8+ T cell 
population and it has also been observed that following primary infection, responses against 
proteins from the latent cycle account for up to 5% of circulating CD8+ T cells. The dominant 
responses are generally against epitopes drawn from the EBNA3 family of proteins and to a 
lesser extent LMP2 (reviewed in Hislop et al., 2007). During resolution of the acute disease, 
most of the T cells undergo apoptosis, leaving a small proportion in the memory population 
that control the persistent infection. 
Until recently, there has been a disparity in knowledge of the CD4+ T cells response to EBV 
compared to CD8+ T cells. A lack of information regarding individual epitope responses, the 
lower frequency of virus specific CD4+ T cells in the blood and a paucity in reagents such as 
MHC class II tetramers to enable the analysis of epitope specific cells CD4+ T cells, have all 
caused difficulty in analysing the CD4+ T cell response to EBV. However recent elucidation of 
the epitopes recognised by EBV-specific CD4+ T cells (Long et al., 2005, 2011) and the 
improved reproducibility of testing performed with MHC class II tetramers (Long et al., 2013) 
have meant that some of these experimental and technological issues have been overcome. 
Recent studies show that CD4+ T cells against lytic and latent proteins (except EBNA1) are 
expanded in the blood of IM patients, but to a lesser extent than their CD8+ counterparts 
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(Long et al., 2013). Furthermore, CD4+ T cell responses are maintained in memory at low 
frequency but are spread throughout immediate early, early and late proteins of the lytic 
cycle as well as across the latent EBNA proteins (Long et al., 2011). Thus, individual CD4+ 
responses are lower than CD8+ responses but are spread over a broader repertoire. 
 
1.3 EBV associated malignancies and immunotherapy 
The balance between the virus and the immune system allows most individuals to stay 
asymptomatic, but the virus does have oncogenic potential. Therefore, despite the T cell 
surveillance,  EBV is associated with a  number of haematological and epithelial 
malignancies including Burkitt’s lymphoma (BL) Hodgkin’s lymphoma (HL), nasopharyngeal 
carcinoma (NPC), some gastric carcinomas, diffuse large B-cell lymphoma (DLBCL), NK/T 
cell lymphoma and, in individuals undergoing therapeutic immunosuppression, post-
transplant lymphoproliferative disease (PTLD).  
The expression of viral proteins by these cancerous cells make them ideal candidates for T-
cell based immunotherapy as they can be directly recognised and killed by cytotoxic T cells 
specific for such antigens. In particular the use of adoptive transfer of polyclonal EBV-specific 
T cells has proved to be a highly successful way of treating PTLD. 
At present, PTLD is the only EBV related malignancy that is treated with infusion of EBV 
specific CTLs. These cytotoxic lymphocytes are generated by stimulation with in vitro 
generated autologous lymphoblastoid cell lines (LCLs). These EBV-transformed cells 
express the full range of EBV latent proteins and resemble tumour cells of PTLD. In a recent 
trial, EBV-specific CTL infusions were administered as a prophylactic to 101 patients who 
had undergone hematopoietic stem cell transplantation (HSCT) and who were deemed to be 
at high risk of developing PTLD. Remarkably, none of these patients have since developed 
the disease. Furthermore, 11 of 13 patients who received EBV-CTLs following clinical 
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diagnosis of EBV-positive PTLD achieved a complete response (Heslop et al., 2010). 
However immunosuppressed patients undergoing solid organ transplant (SOT) only 
responded in approximately 50% of cases (Haque et al., 2007). In HSCT, CTLs generated 
from the allograft have not only been shown to persist in the circulating memory pool but also 
to expand in response to antigen challenge. This is in contrast to infusion of patient derived 
EBV-specific CTLs following SOT as they struggle to persist in the presence of continuous 
immunosuppression. 
It has been thought that the particular success of this treatment was due to the high 
proportion of cytotoxic CD8+ T cells in the EBV-specific preparations. Recent evidence 
however suggests that responses are greatly improved with a higher percentage of CD4+ T 
helper cells (Haque et al., 2007). Unlike CD8+ T cells whose specificity is conferred through 
MHC class I recognition, CD4+ T cells recognise antigens bound to MHC class II molecules 
which predominantly arise from the extracellular processing pathway of antigen presenting 
cells. Nonetheless, it has been shown that in some cases epitopes can gain direct access to 
the MHC class II processing pathway (Leung et al., 2010; Nedjic et al., 2009). In addition, like 
CD8+ T cells, CD4+ T cells are also capable of functioning as effectors through cytotoxicity in 
a peptide-specific and MHC class II restricted manner (Suni et al., 2001). In the context of 
viral infections and cancers occurring in MHC class II positive cells (such as EBV and its 
associated malignancies), CD4+ T cells therefore represent an interesting area to study for 
therapeutic applications. 
Despite the positive correlation between frequency of EBV specific CD4+ T cells in CTL 
infusions and the clinical outcome, we do not currently know anything about their functional 
characteristics or which epitopes have the greatest clinical effect. 
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1.4 CD4+ T cells in immunity and infection 
CD4+ T cells play a central role in immunity and responding to viral infections by 
orchestrating the response of multiple wings of the immune system. CD4+ T cells interact 
with CD8+ T cells by secreting IL-2 and promote differentiation as well as enhancing both the 
primary and memory antiviral responses of cytotoxic CD8+ T cells. They also play a vital role 
in stimulating antigen presenting cells by secreting IFNγ but also through the binding of 
CD40 to its associated ligand that is present on the surface of activated CD4+ T cells. These 
signals enhance antigen processing and presentation on the surface of macrophages and 
dendritic cells while also boosting antibody mediated immune response by increasing 
memory B cell and plasma cell differentiation (Fig 1.1).  
 
Figure 1.1 CD4
+
 T cells play a central role in the immune system response to viral infections by 
orchestrating the activity of cytotoxic CD8
+
 T cells, dendritic cells, macrophages and B cells. 
(Whitmire, 2011) 
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The example of HIV infection gives the clearest indication of CD4+ T cells’ critical importance 
as disease progression to AIDS occurs when CD4+ T cells are at extremely low levels and 
are therefore unable to orchestrate an efficient immune response to opportunistic infections.  
For all the complex functions that CD4+ T cells carry out, they can differentiate into a number 
of different subsets. The differentiation from a naïve CD4+ T cell into a subpopulation occurs 
once an antigen in complex with MHC class II molecules is recognised by its cognate T-cell 
receptor (TCR). The lineage a cell is subsequently differentiates to is influenced by the 
resulting strength of the TCR signal as well as cytokines present in the extracellular 
environment and the type of antigen presenting cell (ligation of different types of co-
stimulatory molecules) (Murphy, Reiner, 2002).    
The Th1 and Th2 subtypes are perhaps the most extensively studied effector helper cells and 
are heavily associated with the expression of the transcription factors T-bet and GATA3 
respectively. Beyond these two classical subsets, which are the main effector subsets 
involved in host immunity against viral/microbial infections and extracellular parasites 
respectively,  a number of new lineages are now know to also play role in the adaptive 
immune system. Th9 and the closely related Th17 and Th22 effector subsets possess a 
variety of different functions ranging from defence against parasitic infections (Th9) to anti-
microbial immunity at mucosal sites (Th17) and wound healing (Th22). Much like the Th1 and 
Th2 subsets, each lineage also secretes specific cytokines: IL-9 for Th9, IL-17and IL-22 for 
Th17, IL-22 and TNFα for Th22 cells (reviewed by Luckheeram, 2012) (Fig1.2). Differentiation 
to a particular effector subtype was previously thought to be an irreversible process however 
research now suggests that CD4+ T cells are capable of remaining plastic (Murphy, 
Stockinger, 2010). The exact mechanisms underlying this ability to change subtype is not 
well understood, nonetheless factors such as the differentiation state and epigenetic changes 
are thought to influence this plasticity (Murphy et al., 1996; Hirahara et al., 2011). 
Furthermore, recent experimental evidence has demonstrated that cytokines secreted by the 
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different subsets are able to affect the characteristic profile of helper cells. It has been shown 
that transforming growth factor-β, a cytokine predominantly associated with promoting the 
differentiation of naïve CD4+ T cells into Th17 or Treg subsets, can cause the “reprogramming” 
of Th2 cells to an IL-9 secreting profile associated with the Th9 subset (Veldhoen et al., 2008). 
Moreover the localised presence of IL-6, IL-23 and TGF-β and interaction between the 
transcription factors FoxP3 and RORγt play a siginificant role in the interconversion that can 
occur between the regulatory and TH17  subsets (reviewed by Tato and Cua, 2008).  
In addition to the “helper” subsets, CD4+ T cells can also differentiate into subtypes that play 
a role in the regulation of the immune system. Regulatory T cells (Tregs) and follicular helper 
cells (TFH), as their names suggest, regulate the immune response and help in the 
maintenance of germinal centres (stimulating antibody production by B cells) respectively. 
Tregs exert their role by secreting immunosuppressive cytokines such as IL-10 and TGFβ and 
are characterised by the presence of the FoxP3 transcription factor and high expression of 
CD25 on the cell surface (Vignali 2008). Meanwhile TFH cells migrate to B cell follicles due to 
the expression of the homing receptor CXCR5 and signal to plasma cells and memory B 
cells through the secretion of CD40L, IL-4 and IL-21 (Crotty, 2011) (Fig 1.2).  
The majority of research into anti-viral CD4+ T cells has focused on looking at the secretion 
of IFNγ by responding cells however mounting evidence suggests that polyfunctional CD4+ T 
cells that produce multiple cytokines and perform multiple functions are of vital importance in 
controlling viral infections as they can exert more effective control (Makedonas, Betts, 2006). 
In patients who have undergone liver transplant, presence of polyfunctional CD4+ T cells 
specific for the herpesvirus CMV, protect against high-level replication of the virus (Nebbia et 
al., 2011).  Additionally, studies have recently shown that subjects with higher proportions of 
polyfunctional T cells are more able to spontaneously control HIV infection (Van Braeckel et 
al., 2012).  In the context of EBV, it has been shown that in patients suffering from PTLD, 
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frequency of polyfunctional T cells specific for EBV were significantly decreased compared to 
asymptomatic long term carriers of the virus (Ning et al., 2011).  
 
 
Figure 1.2. Naïve CD4
+
 T cells can differentiate into a variety of different subsets associated with 
expression of transcription factors and production of cytokines. (Russ 2013) 
 
Along with secretion of effector cytokines, CD4+ T cells can possess cytotoxic abilities. 
Although it was originally thought that the capacity to kill antigen expressing targets was only 
a feature of CD8+ T cells, it is now clear that in certain circumstances CD4+ T cells can also 
exhibit cytotoxic function on MHC class II positive cells expressing their cognate antigen. The 
polarizing conditions that determine CD4+ subtype differentiation also influences their 
cytotoxic potential. Thus, research has shown that Th1 effectors exhibit high levels of 
granzyme B whereas Th2 effectors (and to an extent Th17 cells) possess much lower levels 
and are therefore thought to be less able to lyse target cells (Brown et al., 2009).  
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Induction of lysis of cells targeted by CD4 T cells is mediated through apoptotic pathways 
and can occur through a number of distinct mechanisms. Perforin and granzyme B are 
released by cytotoxic CD4+ T cells and while the former creates pores within the plasma 
membrane of a target cell, granzyme B can enter a cell to cleaves and activate pro-apoptotic 
proteins.  Additionally, binding of Fas receptor on target cells to its cognate ligand FasL on 
the surface of the T cell or binding of the TNF related apoptosis inducing ligand (TRAIL) 
present on the T cell to death receptors can initiate signal transduction pathways of 
apoptosis (reviewed by Brown, 2010; Herbeuval et al., 2005).  
The mechanism employed by a cytotoxic CD4+ T cell is linked with the differentiation status 
of CD4+ T cells. Indeed CD4+ T cells express cell surface receptors depending on their 
activation and migration state. Naïve T cells (TN) express high levels of CD45RA and the 
lymphoid homing markers CD62L and CCR7, however following activation (contact with an 
antigen presenting cell), the phenotype changes.  Expression of CD45RA switches to its 
isoform CD45RO and cells can be subdivided into either CCR7+ CD62Lhi central memory 
cells (TCM) that will migrate to the lymphoid tissue or, CCR7
- CD62Llow effector memory cells 
(TEM) that will produce cytokines such as IFNγ and IL-4 (Fig 1.3.a). The latter are also know 
in some circumstances to express high levels of perforin and granzyme (Appay et al. 2002). 
An additional effector memory population that is positive for CD45RA, called TEMRA, exists 
and represent the most differentiated type of CD4+ T cell. It is however believed that in the 
case of chronic infections such as EBV, where T cells are constantly being exposed to 
antigens, a population of terminally differentiated effector cells with cytotoxic potential is 
present in the blood (Fig1.3.b). This particular phenotype is also what is acquired by cultured 
CD4+ T cell clones over time. 
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Figure 1.3 (a) Memory phenotype of CD4
+
 T cells is associated with, but not exclusively linked to, cell 
surface expression of, the differentiation marker CD45RA and the lymphoid homing marker CCR7. (b) 
Model for cytolytic CD4
+
 T cells with increasing cytotoxic potential and cytokine productions in chronic 
infections through repeated challenge with antigen. (Adapted from Brown, 2010). 
 
 
1.5 Therapeutic use of CD4+  T cells 
There is therefore potential for CD4+ T cells to be used therapeutically, particularly in the 
case of EBV associated malignancies where the target B cell constitutively express MHC 
class II molecules on the surface. In the case of Burkitt’s lymphoma, tumours are deficient in 
class I antigen processing thereby allowing them to evade recognition by CD8+ T cells. 
However, they retain a degree of class II function and as a result can be targeted by CD4+ T 
cells (God, Haque, 2010). 
Recently, infusion of an expanded CD4+ T cell clone specific for a melanoma associated 
antigen into a patient with refractory metastatic melanoma mediated a durable clinical 
remission (Hunder et al., 2008). This demonstrated the potential for cytotoxic CD4+ T cells to 
be used in cancer immunotherapy in general and not necessarily restricted to EBV 
associated cancers. 
(a) (b) 
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In the context of this virus it is now known what epitope responses are present in the 
circulating blood of healthy donors, but most ex vivo studies have been limited to the analysis 
the production of IFNγ and or IL-4 (Bickham et al., 2001; Long et al., 2011). However, 
phenotyping of EBV specific CD4+ T cells by looking at the expression of transcription factors 
has not been performed alongside cytokine profile analysis. 
In addition to analysing cytokine production, studies have shown that in vitro isolated EBV-
specific CD4+ T cells clones can kill EBV infected cells (Long et al., 2005; Munz et al., 2000) 
and preferentially use perforin/granzyme dependent mechanism (Haigh et al., 2008; 
Khanolkar et al., 2001). However, as mentioned previously, such CD4+ T cell clones kept in 
culture need to be constantly challenged with antigen and therefore adopt a late 
differentiated memory phenotype which is associated with a higher presence of cytotoxic 
molecules and increased production of cytokines. Circulating EBV specific CD4+ T cells are 
predominantly central or effector memory cells and it has yet to be studied whether these are 
primed for direct cytotoxic capacity. Such studies would enable us to confirm whether 
cytotoxic EBV-specific cells are present in the circulation or whether what has been 
previously observed is in fact an artefact of in vitro culture of  CD4+ T cell clones. Assessing 
the frequency of un-manipulated EBV specific cells expressing perforin and granzyme as 
well as their ability to directly recognise and kill virus infected cells would further enhance our 
understanding of the importance of these cytotoxic CD4+ T cells in controlling the virus.  
Understanding the functional characteristics of CD4+ T cells that are important in controlling 
EBV in healthy donors will help recognize the type of T cells that may be important 
therapeutically. As a result this could help enhance the efficacy of adoptive T cell therapy 
and potentially identify CD4+ T cells that would assist in induction of therapeutic vaccines for 
EBV associated diseases. 
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1.6 Aims 
The aims of this project were therefore: 
1. To design and optimise panels of antibodies to analyse transcription factor 
expression, cytokine production, memory phenotype and cytotoxic potential of EBV-
specific CD4+ T cells. 
2. To use these panels to investigate the cytokine profiles and effector subsets of CD4+ 
T cells responding to autologous EBV-transformed LCLs ex vivo. 
3. To use novel MHC class II EBV tetramers to analyse the cytokine profiles, 
transcription factor expression and cytotoxic potential of individual CD4+ T cells 
responding to EBV-derived-peptides at an epitope level.  
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2. MATERIALS AND METHODS 
2.1 Ethic statements and donors 
All experiments were approved by the South Birmingham Local Research Ethics Committee 
(07/Q2702/94) and all donors provided written consent for the collection of blood samples 
and their subsequent analysis. The cohort consisted of 9 EBV seropositive donors whose 
HLA II type included DR7 (HLA DRB1*07), DR52b (HLA DRB3*02), DR51 (HLA DRB5*01) 
and DR17 (HLA DRB81*0301) or combinations thereof. 
2.2 Cell preparations 
PBMCs from healthy EBV seropositive donors were separated by Ficoll-Hypaque 
centrifugation into RPMI 1640 (Sigma) containing 100IU/mL penicillin and 100µg/mL 
streptomycin (standard medium). Cells were either used immediately or frozen for later use. 
Depletion of CD8+ T cells was achieved by washing cells in RPMI 1640 containing no serum 
and incubating them in a 15mL tube with CD8 Dynabeads (Life Technologies) (approximately 
4 beads per CD8+ T cell) for 30 mins at 4°C on a rotator. CD8+ cells were removed by placing 
the tube in a magnet for 2mins and harvesting the CD4+ T cell enriched supernatant.  
2.3 Lymphoblastoid cell line (LCL) generation 
PBMC pellets were resuspended in supernatant from the Marmoset B95.8 producer line 
filtered through a 0.45µm filter. Cells were left at 37˚C overnight before washing twice in 
RPMI and resuspending in standard medium supplemented with 1µg/ml cyclosporine A.  
Cells were maintained in RPMI with 20% FCS for 2 weeks and in RPMI  8% FCS thereafter. 
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2.4 Intracellular cytokine staining following staphylococcus enterotoxin B (SEB) or 
LCL stimulation or EBV peptide stimulation 
a. Cell stimulation  
Approximately 1x106 (SEB stimulation) or 2x106 (LCL and peptide stimulations) CD8+ 
depleted T cells were placed into tubes for each experimental condition. Tubes for unstained 
control and appropriate compensation tubes were also prepared. Cells were either, 
stimulated with the superantigen SEB at a final concentration of 0.2µg/mL, or incubated with 
autologous LCLs at a ratio of 1:1, or incubated with EBV peptides (Alta Bioscience, see 
Table 2 for sequences) at concentrations ranging from 5µg/mL to 0.005µg/mL, or left 
unstimulated and placed at 37°C, 5% CO2. All cells were gently resuspended every 15 mins 
for the first hour, after which Brefeldin A (BFA) (final concentration 0.2µg/mL) was added and 
the tubes placed back at 37°C overnight. 
b. Viability and Surface Staining 
The following day cells were washed in PBS using a standard centrifugation (2000rpm, 
5mins) and stained with a 1:100 dilution of live/dead fixable aqua cell stain kit (Invitrogen) for 
20 minutes in the dark at room temperature. After washing away excess stain with PBS, cells 
were stained for surface markers using various combinations, as described in the results for 
each experiment, of pre-determined saturating concentrations of the following antibodies: 
CD3 (AmCyan –conjugated, clone SK7, BD), CD4 (ECD-conjugated, clone SFCI12T4D11, 
Beckman Coulter), CD14 (clone HCD14) and CD19 (clone HIB19) (both Pacific Blue-
conjugated, both Biolegend) on ice for 20 minutes.  
c. ICS for cytokines and transcription factor expression 
After a wash with PBS, cells were fixed by incubation with Fixation concentrate (Foxp3 / 
Transcription Factor Staining Buffer Set, eBioscience) for 30 mins on ice and subsequently 
permeabilized by performing two washes with Permeabilization buffer (same kit). Relevant 
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volumes and combinations of the following antibodies were added to the experimental tubes 
(Table 1) which were left at room temperature for 30 mins : IFNγ (FITC- labelled, clone 
4S.B3), IFNγ (Alex Fluor 700-labelles, same clone) TNFα (PE-Cy7, clone MAb11), IL-10 (PE-
Cy7, clone JES3-9D7), IL-2 (Alexa Fluor 700, clone MQ1-17H12), IL-2 (PerCP-Cy5.5-
labelled, same clone) IL-21 (APC, clone 3A3-N2), GM-CSF (PerCP-Cy5.5, clone BVD2-
21C11) (all Biolegend), IL-4 (PE-Cy7,  clone 8D4-8), T-bet (eFluor 660, clone 4B10), FoxP3 
(APC, clone 236A/E7) (all eBioscience), GATA3 (Alex Fluor 488, clone L50-823, BD).  
Cells were analysed on an LSRII flow cytometer (Beckman Coulter) and data was processed 
using FlowJo software (Treestar, OR, USA). 
2.5 EBV MHC class II tetramer staining 
MHC class II tetramers representing the HLA allele – EBV epitope combination shown in 
Table 2. (manufactured by “The tetramer core facility of the Benaroya Research Institute”, 
Seattle, WA) were tested against appropriate donor PBMCs based on their HLA-DR type. To 
perform the staining, CD8 depleted PBMCs were washed in human serum followed by 
addition of relevant PE labelled tetramers, or no tetramer for control tubes, and were 
incubated for 1 hour at 37°C with gentle resuspension every 15 mins. Vital dye and surface 
staining were performed as described in section 3, and cells were fixed in 4% 
paraformaldehyde before analysis on the LSR II.  
2.6 Combination of MHC II Tetramer and intracellular cytokine  staining following 
peptide stimulation 
CD8 depleted PBMCs from DR7- or DR52b-positive donors were stimulated with 0.005µg/mL 
of the PRS peptide for 4 hours, with addition of BFA after the first hour of incubation. 
Following one wash in human serum, MHC II tetramer staining was conducted as detailed in 
section 5, followed by viability, surface and ICS for cytokines and transcription factors as 
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described in section 4. Cells were analysed on an LSRII flow cytometer (Beckman Coulter) 
and data was processed using FlowJo software (Treestar, OR, USA). 
2.7 EBV specific CD4+ T cell phenotyping 
Following MHC class II tetramer and vital dye staining, CD8 depleted PBMCs were surface 
stained using saturating concentrations of CD3, CD4, CD14, CD19 (same as above), 
CD45RA (Alexa Fluor 700 labelled, clone HI100, Biolegend) and CCR7 (Brilliant Violet 650 
labelled, clone 3D12, BD) on ice for 20 mins. Subsequent to a wash with PBS, cells were 
fixed by incubation with 2% PFA for 20 minutes at room temperature. Following successive 
washes with PBS/2% BSA and saponin buffer (PBS, 0.5% FCS, 0.5% w/v saponin), cells 
were left to permeabilize for 20 minutes at room temperature. Experiment tubes were then 
incubated with Perforin (PE-Cy7 labelled, clone dG9, ebioscience) and Granzyme-B (Alexa 
Fluor 647 labelled, clone GB11, Biolegend) for 30 minutes at room temperature. Finally, cells 
were washed with PBS/2 % BSA and resuspended in 2% PFA before analysis on LSRII. 
 
 
 
 
Table 1. MHC II tetramer reagents 
  
     Virus phase Protein Coordinates Epitope MHC II restriction 
Latent EBNA1 (E1) 474-493 SNPKFENIAEGLRVLLARSH DRB5*01:01 (DR51) 
Latent EBNA2 (E2) 276-295 PRSPTVFYNIPPMPLPPSQL DRB1*07:01 (DR7) 
Latent EBNA2 (E2) 276-295 PRSPTVFYNIPPMPLPPSQL DRB3*02:02 (DR52b) 
Latent EBNA2 (E2) 301-320 PAQPPPGVINDQQLHHLPSG DRB1*03:01 (DR17) 
Lytic BMRF1 136-150 VKLTMEYDDKVSKSH DRB1*03:01 (DR17) 
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3. RESULTS 
3.1 Optimisation of antibody panels for CD4+ T cell phenotype and function    
identification 
To enable characterization of the phenotype and functional capacity of EBV specific CD4+ T 
cells in the blood of healthy seropositive donors, several antibody panels were set up. Using 
these panels the aim was to assess expression of specific transcription factors associated 
with various CD4+ T cell subsets within the EBV-specific populations, and their production of 
a range of cytokines when challenged with antigen. Additionally we also wished to measure 
levels of proteins associated with cytotoxic function and correlate those with memory status 
of the cells by assessing expression of phenotypic markers on the cell surface of virus 
specific CD4+ T cells.  
In order to achieve these aims, initial experiments to optimise the concentrations of 
antibodies present in these panels, that had not previously been used in the laboratory, were 
carried out. All new antibodies were tested at a number of different concentrations, guided by 
the manufacturer’s recommended dilution, on CD8+ depleted PBMCs of healthy donors. All 
tests were performed alongside surface staining of CD3 AmCyan, CD4 ECD, CD14 and 
CD19 Pacific Blue (B cell and macrophage surface markers respectively)  as well as vital dye 
(also on Pacific Blue) to allow the analysis of experimental antibodies binding to viable CD3+ 
CD4+ cells. 
An example of the gating strategy for viable CD3+ CD4+ cells is shown in Fig 3.1.a. Firstly, 
lymphocytes were selected using the forward and side scatter (FSC and SSC) plot. Within 
this population, viable, CD14- CD19- cells negative for Pacific Blue staining were isolated 
(middle plot) and CD3+ CD4+ cells within this gate were selected for subsequent analysis 
(right plot). 
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Unless stated otherwise, this gating strategy applied throughout this study and the selected 
CD3+ CD4+ double positive population was further investigated for the characteristics of 
interest in each experiment as described.  
Firstly, surface antibodies to be used for phenotyping and compensation that had not 
previously been used in the laboratory were titrated in order to determine optimal working 
concentrations based on clear defined populations of positive cells and limited background 
staining of negative cell populations. As shown in Fig 3.1.b, the mean fluorescence 
intensities (MFI) of cells positive for CD4 when stained with a Brilliant Violet 650 labelled 
antibody (left plot), do not noticeably change between the manufacturers recommended 
dilution of 1:10 and 1:50. Therefore the latter was chosen as the most appropriate for these 
experiments as the antibody is still in excess at this dilution. Staining with CCR7 (also with a 
Brilliant Violet 650 conjugated antibody, middle plot) and CD127 with a PerCP-Cy5.5 labelled 
antibody (left plot) show different MFI of staining based on the concentration used. From the 
respective histograms it was determined that dilutions of 1:20 for CCR7 and 1:20 for CD127 
be used for this study, as clear populations of cells could be distinguished. An analogous 
approach was used for all other previously un-validated surface antibodies. 
Optimisation of antibodies to be used for intracellular cytokine staining was carried out by 
stimulating CD8+ depleted PBMCs from healthy donors with the superantigen SEB and 
incubating in the presence of Brefeldin A to inhibit protein transport to the Golgi apparatus. 
Following viability and surface staining with CD3, CD4, CD14 and CD19; cells were fixed and 
permeabilised as described in the methods. Different concentrations, using the 
manufacturers’ recommendations as a guide as for titration of surface anitbodies, were 
tested on all new antibodies and two representative results are shown in Fig 3.1.c. Gating 
was set on the unstained control in order to assess whether background staining at the 
varying concentrations caused a shift in the MFI of the entire population. Unstimulated 
controls were stained with the manufacturers’ recommended concentration which was the 
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lowest dilution in each case. Where possible, isotype control antibodies were used to confirm 
no non-specific binding of antibodies (data not shown). 
The results of titrating the Alexa Fluor 700 labelled IL-2 antibody (top plots) demonstrate that 
using the recommended dilution of 1:10 and even 1:200 dilution, lead to a shift of the MFI of 
the negative population, which would result in difficulty in determining positive populations. 
However, further dilutions of 1:1000 and 1:2000 were tested and the former was chosen as 
the optimal dilution for our studies, as the positive population could be clearly distinguished 
without a shift in the total cell MFI. Conversely, staining with the recommended 1:10 dilution 
with the PerCP-Cy5.5 labelled IL-2 antibody (bottom plots) allowed clear visualisation of IL-2 
positive cells, with negative cells showing similar MFI to the unstained populations. In 
addition titrating the antibody down to 1:20 and 1:50 dilutions resulted in lower numbers of IL-
2+ cells being detected indicating the antibody was no longer in excess, and positive cells 
could be missed 
Fig 3.1.d summarises the finalised antibody panels used, with the dilutions used for each 
antibody based on a reaction volume of 50µL. All antibodies optimised during this study are 
identified with an asterisk. 
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Figure 3.1 Gating strategy and antibody titration 
(a) Gating strategy for all flow cytometry analysis.  CD8 depleted PBMCs were gated on lymphocytes 
(based on forward and side scatter), distinguished for negative staining for CD14, CD19 and viability 
dye on Pacific Blue (dump channel). Surface and intracellular staining of CD4
+
 T cells was analysed 
by gating on double positive CD3 and CD4 cells. (b) Histograms representing MFI of PBMCs stained 
with increasing dilutions of either: CD4 BV650 (right hand side), CCR7 BV650 (middle) or CD127 
PerCP-Cy5.5 (left hand side). (c) Intracellular cytokine staining of PBMCs with decreasing 
concentrations of IL-2 AF700 (top) and IL-2 PerCP-Cy5.5 (bottom). (d) Final subsets and optimised 
dilutions for all panels. * indicates antibodies titrated during the project. 
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3.2 Lineage and cytokine profile of EBV specific CD4+ T cells 
It is now accepted that CD4+ T cells can directly recognise and function in response to MHC 
class II positive target cells expressing their cognate antigen. Studies looking at the ability of 
CD4+ T cells to respond to EBV infected cells ex vivo have previously focused on the 
quantification of one or two cytokines (principally IFNγ and IL-4) yet recent studies suggest 
that CD4+ T cell responses to viral infections are heterogeneous and contain polyfunctional T 
cells. To further investigate the profile of CD4+ T cells responding to EBV infected cells, CD8+ 
depleted PBMCs from six EBV seropositive donors were stimulated with their autologous 
EBV-transformed lymphoblastoid cell lines (LCLs) overnight in the presence of Brefeldin A. 
Three of the donor LCLs were not readily available and were therefore generated during this 
study by infecting donor PBMCs with supernatant from B95.8 virus producer line in the 
presence of cyclosporin A to abrogate the T cell response. Following the overnight incubation 
with LCL, viability and surface staining for CD3, CD4, CD14 and CD19 was performed as 
described earlier.  Cells were subsequently fixed and permeabilised to enable intracellular 
staining for Th1, Th2 and Treg T cell subset associated transcription factors and cytokines as 
described in Fig 3.1.d 
For this series of experiments, following gating on lymphocytes and viable CD14- CD19- cells, 
PBMCs were gated on CD3+ rather than CD3+ CD4+ as shown in Fig 3.2.a. This is because 
expression of CD4 can be down regulated following T cell activation and therefore using the 
strategy shown in Fig 3.1.a (right plot) might lead to responding cells being lost from the 
analysis. 
 
In order to study the response of Th1 type CD4
+ lymphocytes, following the surface staining 
described above, cells were stained for the transcription factor T-bet along with the cytokines 
IFNγ, TNFα, IL-2 and GM-CSF. Analysis of these cells was performed by gating on the CD4+    
T-bet+ cells shown in Fig 3.2.b (top plot, top right quadrant Q2). As can be seen from this 
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plot, the vast majority of CD4+ T cells in the peripheral blood are positive for T-bet and 
approximately 80% of the CD4+ enriched PBMC population shown here are CD4+ T cells 
expressing the Th1 associated transcription factor. Subsequently the percentage of LCL 
stimulated cells producing Th1 like cytokines within the total CD4
+ population (left hand plots) 
and T-bet+ CD4+ population (right hand plots) were analysed. 
Low background frequencies of TNFα and GM-CSF producing cells were observed in the 
unstimulated populations of both the total CD4 lymphocytes and T-bet+ gated cells. Similar 
low numbers of IFNγ and IL-2 producing cells were also observed in the total CD4+ 
population but these did not appear to be amongst the T-bet+ population. 
LCL stimulation resulted in the total frequency of IFNγ producing cells increasing from 
0.095% to 0.480% in the total CD4+ population and from 0.050% to 0.045% in the T-bet+ 
population. Similarly, the percentage of cells producing TNFα increased from 0.579% to 
0.791% and from 0.570% to 0.741% for the total CD4+ and T-bet+ populations respectively. 
However, while the percentage of cells producing IFNγ alone increased by approximately 
0.1%, the frequency of cells producing just TNFα decreased slightly and the vast majority of 
cells responding to the presence of LCLs produced both IFNγ and TNFα. This population 
was not observed in the unstimulated populations but accounts for 0.278% of total CD4+ cells 
and 0.268% of T-bet+ LCL stimulated cells. Interestingly percentages of cells producing IL-2 
remained unchanged between the unstimulated and stimulated cells in both the total CD4+ 
population and the T-bet
+ population and no production of GM-CSF was detected. These 
results show that CD4+ cells activated by EBV infected cells, which express the Th1 
associated transcription factor secrete IFNγ alone or a combination of IFNγ and TNFα. 
 
Control of viral infections is most commonly associated with the Th1 subset of CD4
+ T due to 
the secretion of its associated anti-viral cytokine IFNγ, however studies have suggested that 
some T cells responding to LCLs are capable of releasing the Th2 associated cytokine IL-4. 
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Thus, in the second panel, cells were stained for the Th2 associated transcription factor 
GATA3 and associated cytokines IL-4 and IL-21. Levels of IFNγ and IL-2 were also assessed 
in this panel for comparison purposes. The frequency of Th2 CD4
+ lymphocytes within the 
total CD4+ T cell enriched population was analysed by staining cells for the transcription 
factor GATA3, a representative example of which is shown in Fig 3.2.c. In this donor the 
percentage of peripheral cells expressing GATA3 was 2.02%. As a result, the cytokine 
profiles of fewer cells could be analysed compared to the Th1 subset, however in a parallel 
way to the previous panel, the unstimulated and LCL stimulated cells of the CD4+ GATA3+ 
population (right plots) was compared to the total CD4+ population (left plots). In the 
representative example shown here, the frequency of IL-4 producing cells in the  
unstimulated total CD4+ population was 2.59% but noticeably this was only enriched to  
4.99% when the GATA3+ CD4+ T cells were were analysed. Interestingly, following 
stimulation the frequency of IL-4 producing cells did not increase either in the total CD4+ T 
cell population, or in the GATA3+ cells. Similarly, the GATA3 positive cells did not produce IL-
21 or IL-2 upon stimulation. Interestingly, the percentage of IFNγ producing cells in the total 
CD4+ population increases from 0.03% to 0.33% after stimulation, confirming the result seen 
in Fig 3.2.b. Notably, none of the GATA3+ CD4+ T cells produced IFNγ in response to 
stimulation demonstrating that production of this cytokine does not occur when the Th2 
transcription factor is expressed. Overall, these results suggest that the GATA3 positive Th2 
subset is not activated by exposure to EBV infected cells. 
 
The final panel was set up in order to establish whether any CD4+ T cells amongst the 
population activated by autologous LCLs possessed the characteristics of a regulatory T cell. 
To achieve this, cells were stained for the Treg associated transcription factor FoxP3 and for 
the immunosuppressive cytokine IL-10. Again, IFNγ production was also measured for 
comparison. In order to look at the response of Tregs to EBV infected PBMCs, we gated on 
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CD4+ cells positive for the transcription factor FoxP3, as shown in Fig 3.2.d (top plot). T 
lymphocytes expressing the FoxP3 transcription factor in the donor shown represented 3.7% 
of the total circulating population, in line with published normal ranges (appropriate ref). The 
cytokine profile of the resulting FoxP3+ CD4+ cells (shown in the right hand plots) would be 
compared to that of the total CD4+ population (left hand plots). A low percentage of 
unstimulated cells in the total CD4+ population produced IL-10 and IFNγ but this did not 
appear to be directly associated with expression of FoxP3. Following LCL stimulation, the 
percentage of cell producing IL-10 did not change dramatically in either the total CD4+ 
population or the FoxP3+ CD4+ populations. However, in line with the data presented for the 
Th1 and Th2 panels (shown in Fig 3.2.b and 3.2.c) the percentage of IFNγ producing cells 
increased in the total CD4+ population from 0.07% to 0.41%. Perhaps more striking was that 
LCL stimulation provoked a response in the FoxP3+ population. Thus, 0.86% of cells positive 
for the Treg associated transcription factor appeared to produce IFNγ in reponse to LCL 
stimulation, a cytokine whose expression has not routinely been linked with this type of 
regulatory T cell. The results obtained by staining with this third panel of antibodies show that 
a small percentage of FoxP3 expressing CD4+ T cells may be able to respond to autologous 
LCL stimulation by production of IFNγ and not of the more commonly Treg associated 
cytokine IL-10.  
 
As mentioned previously, analysis of cytokine production by CD4+ T cells activated by EBV 
infected cells has mainly been measured through the secretion of IFNγ. This cytokine is 
associated with anti-viral responses and is known to stimulate cytotoxic CD8+ T cells and 
phagocytic macrophages. The anti-IFNγ antibody was included in all three of the panels 
tested, acting as an internal control and production of IFNγ was always observed in the total 
CD4+ population after incubation with LCLs (Fig 3.2.b, 3.2.c and 3.2.d). In order to confirm 
the transcription factors expressed in the CD4+ T cells that were producing IFNγ following 
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LCL stimulation, in the final analyses the gating strategy was reversed. Thus, expression of 
T-bet, GATA3 and FoxP3 was analysed in CD4+ T cells producing IFNγ. Fig 3.2.e shows a 
representation of the IFNγ producing cells between unstimulated and LCL stimulated 
conditions (top). The frequencies of T-bet, GATA3 or FoxP3 positive cells within the IFNγ-
producing cells was subsequently assessed (bottom). The staining shows that the vast 
majority (over 80% in all donors) of IFNγ producing cells are of a Th1 lineage, expressing T-
bet. The Th2 GATA3 subset does not produce IFNγ and a small proportion of cytokine 
secreting cells express FoxP3. The latter result confirming the detection of IFNγ observed 
when gating on FoxP3+ cells (Fig 3.2.d).  
 
In summary, this data demonstrate that CD4+ T cells can directly respond to EBV infected 
LCLs ex vivo by producing effector cytokines. Furthermore, the vast majority of responding 
CD4+ T cells are of a Th1-like phenotype, expressing T-bet and producing IFNγ and TNFα, 
with a minority population of cells expressing the regulatory T cell associated transcription 
factor FoxP3. 
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(c)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 CD4
+
 T cell response to autologous LCL stimulation 
(a) Analysis of T cells responding to LCL stimulus done by initially gating on CD3
+
 T cells to take into 
account downregulation of CD4 following activation. Expression of Th1 (b), Th2 (c) and Treg (d) 
associated transcription factors and cytokines analysed in total CD4
+
 population and transcription 
factor positive CD4
+
 T cells. For each panel, the top plot shows the expression of transcription factor in 
the total CD4
+
 population. Production of cytokines in the total CD4
+
 T cell population (left hand side) 
and transcription factor expressing CD4
+ 
T cells (right hand side) in unstimulated (left plots) and LCL 
stimulated (right plots) are shown. (e) Expression of T-bet (left hand), GATA3 (middle) and FoxP3 
(right hand) shown in CD4
+
 T cells producing IFNγ following LCL stimulation. 
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3.3 Frequency of CD4+ EBV epitope MHC class II tetramer responses in healthy 
seropositive individuals 
Having identified the profile of transcription factors and cytokine expression in CD4+ T cells 
responding to EBV infected cells, we wanted to compare the response of CD4+ cells specific 
for individual epitopes derived from latent and lytic EBV proteins. These experiments used 
novel EBV-peptide:MHC class II tetramer reagents, to analyse the functional and 
phenotypical characteristics of EBV specific T cells at the epitope level for the first time. A 
previous study has demonstrated the specificity and reproducibilityof these novel MHC class 
II reagents (Long 2013), but also that CD4+ T cells specific for a given EBV epitope can be 
present at very low frequencies. In order to analyse the highest number of CD4+ T cells 
specific for lytic and latent epitopes, donors with the largest response needed to be identified.  
The five MHC class II tetramers used in this work are listed in Table 1 and each represent a 
different MHC class II allele-EBV epitope combination. The first tetramer tested contained an 
EBNA1 epitope (SNP) restricted to the DRB5*01:01 (DR51) allele. Two tetramers were 
directed against the same PRS epitope derived from the latent protein EBNA2 but presented 
through two distinct MHC II restricting alleles: DRB1*07:01 (DR7) and DRB3*02:02 (DR52b). 
Finally, two DRB1*03:01 (DR17) restricted tetramers against an EBNA2 derived epitope 
(PAQ) and an epitope the lytic protein BMRF1 (VKL) were also tested.   
CD8+ depleted PBMCs from donors expressing one or more of the HLA-DR alleles of interest 
were stained with relevant tetramer followed by viability and surface staining for CD3, CD4, 
CD14 and CD19. Gating was done on CD3+ CD4+ cells as shown in Fig 3.1.a followed by 
assessment of tetramer-PE positive cells within the CD3+ CD4+ population. 
 
Representative responses from donor PBMCs stained with for each EBV peptide:MHC II 
tetramer are shown in Fig 3.3.a. PBMCs stained with surface antibodies and no tetramer are 
shown as controls (left hand plots) alongside responses following incubation with tetramer 
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(right hand plots). No background levels of PE positive cells in the absence of the tetramer 
were detectable for all five EBV epitopes. Amongst the results shown, the response to the 
SNP DR51 restricted tetramer was the highest 0.128%, while percentages of PRS+ cells be it 
DR7 or DR52b restricted were similar in the two donors shown at 0.041 and 0.043% 
respectively. The third EBV EBNA2 derived tetramer, PAQ, however gave the lowest 
response of 0.023%. The frequency of CD4+ T cells specific for the epitope derived from the 
lytic protein BMRF1 was 0.041%.  
A summary of the frequencies of epitope-specific T cells obtained by MHC class II tetramer 
staining across all donors tested is shown in Fig 3.3.b. 
Frequencies of SNP-specific cells reached the highest values of the epitopes tested here but 
also gave the most diverse response ranging from 0.128% to 0.054% between 4 donors.  
The response to the PRS tetramers was broadly similar across the DR7 and DR52b 
restricted tetramers and was seen to be just below 0.05% for all except one donor. CD4+ T 
cells specific for the other EBNA2 epitope PAQ were lower ranging from 0.07% to 0.26%. 
Finally, the response to the VKL tetramer was comparable between the three donors ranging 
from 0.041 to 0.058%. Although these responses are low, they are based on analysis of up 
to 1 x 106 cells and were reproducible in further experiments. 
The positive results obtained for EBV peptide:MHC II tetramers across all donors show that 
in circulating cells, CD4+ T lymphocytes specific for both lytic and latent derived epitopes are 
present.  
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FIGURE 3.3 
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Figure 3.3 Tetramer responses in    
healthy EBV seropositive donors  
(a) CD4
+
 enriched PBMCs from 
appropriate HLA allele matched donors 
stained with cognate MHC class II 
tetramer (right hand) or no tetramer (left 
hand). Percentages represent frequency 
of CD4
+
 T cells stained with tetramer. (b) 
Summary of percentage of CD4
+
 T cells 
positive for tetramer for all donors tested. 
Analysed using Kruskal-Wallis one way 
ANOVA; P=0.013. Dunns post-test show 
SNP DR51 and PAQ DR17 were 
significantly different; * = p<0.005 
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3.4 Lineage and cytokine profile of EBV epitope specific CD4+T cells in healthy 
seropositive individuals 
Having identified donors with the largest frequency responses to EBV epitopes, we then 
wanted to investigate the functional characteristics of epitope specific CD4+ T cells ex vivo 
using MHC class II tetramers. This required the combination of stimulation with an EBV 
peptide and staining with the peptide specific MHC class II tetramer. This is a technically 
challenging experiment as the target for the both the peptide and tetramer will be the T cell 
receptor. Thus TCR down-regulation following peptide stimulation may prevent tetramer 
binding. The stimulation protocol used for this study had previously been optimised in the 
laboratory to measure IFNγ release from PRS (EBNA2) specific T cells. Therefore, initial 
experiments to analyse the full functional profile of EBV epitope-specific CD4+ T cells 
focused on the PRS epitope, restricted by the DR7 and DR52b HLA-DR alleles. 
CD4+ enriched PBMCs from donors chosen for their high frequency of PRS specific CD4+ T 
cells were stimulated with PRS peptide (sequence in table 2.) in the presence of Brefeldin A 
for four hours. Viability and surface staining for CD3, CD4, CD14 and CD19 was then 
performed prior to cells being fixed and permeabilised. Intracellular transcription factor and 
cytokines associated with the Th1, Th2 and Treg T cell subsets were stained for using the 
panels in Table 1 and example results are shown in Fig 3.4.b, c and d. 
 
The total CD3+ CD4+ population was gated on as shown in Fig 3.1.a and cells positive for the 
PRS tetramer were analysed as shown in Fig 3.4.a. In the first panel, cells were stained for 
the Th1 associated transcription factor T-bet along with IFNγ, TNFα, IL-2 and GM-CSF. Fig 
3.2.b shows a representation of the results obtained from one example donor. The 
percentage of T-bet+ cells in the total CD4+ population is 76%, in line with the results in Fig 
3.2.b. Interestingly this percentage rises to 88.9% and 82.4% in the unstimulated and 
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stimulated PRS+ populations respectively (top plots), indicating a higher proportion of PRS 
specific T cells express this transcription factor than in the CD4+ population as a whole . 
Background levels of IFNγ secretion in the unstimulated PRS population were negligible 
however 49.1% of the tetramer positive cells did produce TNFα (middle plots), possibly due 
to activation of the cells caused by binding of the tetramer. Stimulation with the PRS peptide 
provoked an increase in IFNγ producing cells from 0.9% to 44.5% and an increase in the 
total frequency of TNFα producing cells to 78.7% amongst the epitope specific T cells. 
Remarkably, the vast majority of IFNγ producing cells were also positive for TNFα, yet 36.1% 
of cells produced the latter cytokine alone. Interestingly19.4% of PRS tetramer positive cells 
in this donor produced neither IFNγ nor TNFα upon stimulation. Background levels of both 
GM-CSF and IL-2 were very low in the unstimulated PRS+ population and the frequency of 
cells producing either cytokine did not significantly increase following incubation with the 
EBNA2 derived peptide (bottom plots).  
 
Fig 3.2.c shows cells from the same experiment stained with antibodies within the second 
panel, used for Th2 subset identification. Staining for the associated transcription factor 
GATA3 (top plot) along with the cytokines IL-4 and IL-21 (bottom plot) were performed. In 
this donor the GATA3+ cells accounted for 2% of the total CD4+ population but no expression 
was seen in the PRS tetramer positive populations. No IL-21 production was seen in the 
unstimulated or PRS stimulated populations however a small increase in frequency of IL-4 
producing cells from 2.82% to 7.23% was observed. Nevertheless, due to the small number 
of cells being analysed here, further analysis is required to confirm this result. 
 
As with the PBMCs stimulated with autologous LCLs, we also wanted to investigate the 
possibility of the presence of EBV epitope specific regulatory T cells. We therefore stained 
cells for FoxP3, IL-10 and IFNγ expression before and after PRS stimulation. The percentage 
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of FoxP3+ cells accounts for 4.41% of the total CD4+ population as shown in Fig 3.4.d (top 
plots), again in line with the percentage of FoxP3 positive cells sen in total CD4+ population 
in Fig 3.2.d . The cells positive for the PRS tetramer however did not appear to also be 
positive for the Treg associated transcription factor. Similarly production of the regulatory 
cytokine IL-10 was not detected in unstimulated or stimulated populations of PRS tet+ cells 
(bottom plots). The frequency of IFNγ producing cells did nonetheless increase from 0% to 
46.9% following stimulation with the PRS peptide confirming the result observed in Fig 3.4.b. 
 
A summary figure of the variations in cytokine expression from the six donors tested is 
shown in Fig 3.4.e. In all donors, T-bet was the principal transcription factor expressed in the 
PRS tetramer positive cells, with no GATA3-positive cells and very few FoxP3-positive cells 
detected. Significant increases between the unstimulated and stimulated populations of PRS 
specific CD4+ T cells in IFNγ and TNFα expression was seen across all donors.  However 
little or none of the other cytokines appeared to be produced in response to incubation with 
the PRS peptide. 
In addition to analysing the response of PRS specific CD4+ T cells we also sought to 
examine transcription factor and cytokine profiles of CD4+ T cells specific for other EBV 
derived antigens to determine whether transcription factor and cytokine profiles seen in the 
context of PRS were consistent across CD4+ T cells specific for different spitopes/stages of 
EBV cycle. Donors with the largest frequency response were chosen to optimise the 
stimulation and the aim was to find a peptide concentration where stimulation would induce 
cytokine production but leave sufficient TCR on the cell surface for MHC II tetramer binding . 
CD4+ enriched PBMCs were stimulated with different concentrations of peptide in the 
presence of Brefeldin A and subsequently stained with the relevant MHC class II tetramer. 
Following viability and surface staining as described above, cells were fixed, permeabilised 
and stained for IFNγ and TNFα. An example of the results obtained for stimulation with the 
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SNP peptide are shown in Fig 3.4.f. Despite using peptide concentrations 100 to 500 fold 
higher than what had previously been established as optimal concentration of PRS peptide, 
staining with the MHC class II tetramer was still possible, indicating that T cell receptors were 
not saturated following stimulation (top plots). We did nonetheless observe a decrease in 
SNP tetramer binding as the concentration of peptide increased. Dropping from 0.227% SNP 
tetramer positive cells when using 0.5µg/mL compared to 0.162% with 2.5µg/mL. In order to 
assess cytokine production from SNP specific CD4+ T cells following stimulation, we 
analysed their production of IFNγ and TNFα. The percentage of IFNγ producing cells did not 
increase over background levels irrespective of the concentration of SNP peptide used 
(middle plots). No cells dually positive for SNP MHC class II tetramer and IFNγ were seen. 
Background levels of TNFα production were similar to what had been previously observed 
when studying PRS specific CD4+ T cells and the frequency of cells producing this cytokine 
did increase with higher concentrations of SNP peptide (bottom plots). However while the 
proportion of CD4+ T cells positive for TNFα went from 0.367% when stimulated with 
0.5µg/mL of peptide to 0.463% when stimulated with 2.5µg/mL, no significant number of cells 
were simultaneously positive for the SNP tetramer. 
We also tried to establish a protocol for the VKL peptide and tetramer without success. 
Further optimisation is required before comparison of T cells specific for different EBV 
eptiopes can be done. 
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FIGURE 3.4 
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(e)  
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Figure 3.4 Intracellular staining of PRS tetramer positive CD4
+
 T cells following EBV peptide 
stimulation 
(a) Analysis of expression of transcription factors and cytokines performed on CD4
+
 T cells positive for 
PRS tetramer staining. Expression of Th1 (b), Th2 (c) and Treg (d) associated transcription factors and 
cytokines analysed in CD4
+
 PRS tetramer
+
 unstimulated and PRS stimulated populations. For each 
panel top left plot shows expression of transcription factor in total CD4+ population. Production of 
cytokines in unstimulated (middle plot) and PRS stimulated (right hand plots) are shown. (e) Summary 
of change in cytokine production following stimulation with PRS in the six donors tested. (f)  Staining 
of SNP tetramer (top plots), IFNγ (middle plots) and TNFα (bottom plots) in the total CD4
+
 population 
following incubation with increasing concentrations of SNP peptide. 
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3.5 Cytotoxic potential and phenotype of EBV epitope specific CD4+ memory T 
cell population  
In the final set of experiments, we wanted to analyse the cyotoxic potential of EBV-specific 
cells ex vivo. Several previous studies performed in vitro have shown that CD4+ T cell clones 
specific for EBV antigens are capable of directly killing infected cells. Expression of high 
levels of cytotoxic molecules required for cytolytic activity in CD4+ T cells has been 
associated with late differentiated cells of a CD45RA+ CCR7- phenotype. Since long-term 
culture of T cells drives differentiation, it is unclear whether such killing activity is an inherent 
property of circulating virus-specific CD4+ T cells or an artefact of in vitro culture. The 
presence of cells with cytotoxic potential ex vivo has not yet been systematically assessed. 
In addition, analysis of the phenotype of EBV specific CD4+ memory cells in the blood of 
healthy carriers has previously shown that the majority lay in the earlier differentiation states 
of CD45RA- CCR7- effector memory (EM) or CD45RA- CCR7+ central memory (CM) 
compartments (Fig 1.3). Furthermore, studies performed at the epitope level on MHC II 
tetramer-binding cells have confirmed this, and shown that majority of CD4+ memory T cells 
have an effector or central memory phenotype. We therefore sought to use our MHC II 
reagents to identify the phenotype of EBV epitope specific CD4+ memory T cells and their 
expression of the cytotoxic molecules Perforin and Granzyme B in the CD4+ memory T cell 
subsets. 
To achieve this, CD4+ enriched PBMCs from donors expressing the DR7 or DR52b alleles 
were stained with the appropriate PRS MHC class II tetramer followed by viability and 
surface staining for CD3, CD4, CD14, CD19, CD45RA and CCR7. Cells were subsequently 
fixed in paraformaldehyde and permeabilised using saponin before, intracellular staining for 
Perforin and Granzyme B was performed. 
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Gating was done on CD3+ CD4+ as show in Fig 3.1.a, followed by assessment of tetramer-PE 
cells within this population (Fig 3.5.a). As shown in Fig 3.5.a, this representative donor has 
0.060% of peripheral CD4+ T cells specific for PRS.  
Cytotoxic potential of PRS specific CD4+ T cells was assessed by analysing the presence of 
Perforin and Granzyme B. As shown in Fig 3.5.b (left plot), only 0.228% of this donor’s CD4+ 
T cell repertoire expresses Granzyme B alone and 0.138% exclusively expressing Perforin. 
CD4+ T cells positive for both cytotoxic molecules accounted for 0.152% of the total CD4+ 
population. Within the PRS specific CD4+ population, no cells expressing Perforin alone were 
observed, nonetheless 7.95% were positive for Perforin and Granzyme B and an equal 
percentage were positive for just Granzyme B.  
A summary graph of the mean frequencies of expression of Perforin and Granzyme obtained 
in the five donors tested is shown in Fig 3.5.c. These initial results show that EBV specific 
cells can possess cytotoxic potential through the presence of Perforin, Granzyme B or a 
combination of the two. Further analysis on larger responses needs to be performed in order 
to confirm these early findings. 
The distribution of CD4+ memory T cell populations in the total CD4+ population and in the 
PRS-specific cells was achieved by looking at expression levels of the differentiation marker 
CD45RA and the lymphoid homing marker CCR7. The example in Fig 3.5.d (left plot) shows 
that 50.2% of the CD4+ population in this donor is made up of naïve T cells (TN) displaying a 
CD45RA+ CCR7+ phenotype. The CD45RA- CCR7+ central memory (TCM) and CD45RA
- 
CCR7- effector memory (TEM) cells represent 35.4% and 12.6% of the total CD4 T 
lymphocyte population respectively. The terminally differentiated effector cells (TEMRA) 
positive for CD45RA but not CCR7 only account for 1.79% of the total CD4+ cells analysed in 
this donor. When the phenotype of PRS specific CD4+ T cells (Fig 3.5.d, right plot) was 
compared, we observed that the percentage of TN was significantly lower at 5.68%. The TCM 
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and TEM populations however were higher at 59.1% and 23.9%% respectively, demonstrating 
that the vast majority of tetramer-binding cells in the blood are antigen experienced, in line 
with the previous observations. The frequency of TEMRA cells was also more abundant in the 
epitope specific CD4+ population of this donor at 11.4%, compared to 1.79%. 
The graph shown in Fig 3.5.e represents the mean frequencies of each memory T cell 
subsets within the CD4+ PRS specific cells across the five donors tested. As for the 
representative example shown, in all donors the majority of EBV epitope specific cells lay in 
the effector populations negative for CD45RA with a small majority being in the central 
CCR7+ population. Only a small percentage can be categorized as CD45RA+. The CCR7+ 
naïve and CCR7- terminally differentiated subsets appear to be present at similar levels.  
These initial tests have support previous findings that at an epitope level the majority of EBV 
specific CD4+ T cells possess either a central or memory phenotype with a small percentage 
of naïve and terminally differentiated cells. Preliminary investigation into the presence of 
cytotoxic molecules has shown that some EBV specific CD4+ T cells, at least, may be primed 
for immediate cytotoxic function against cells expressing their cognate antigen, however, 
these are present at low levels in the circulating blood of healthy donors. 
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FIGURE 3.5 
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Figure 3.5 Cytotoxic potential and phenotype of EBV MHC II tetramer specific CD4 populations 
(a) CD4
+
 T cells positive for PRS tetramer were analysed for their cytotoxic potential and memory 
phenotype. (b) Percentage of total CD4
+
 cells staining for perforin and Granzyme B (left hand) and in 
the PRS tetramer positive cells (right hand). (c) Summary of tetramer positive CD4
+
 cells staining for 
perforin and Granzyme in five donors tested. (d) Percentage of cells stained for CCR7 and CD45RA in 
the total CD4
+
 population (left hand) and  in the PRS tetramer positive population (right hand). (e) 
Summary of tetramer positive CD4
+ 
T cells staining for the memory phenotype markers CCR7 and 
CD45RA in the five donors tested. 
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4. DISCUSSION 
 
The Epstein Barr virus is a B cell tropic agent that is estimated to infect approximately 90% of 
the worldwide population. Despite the virus being tightly controlled by a strong T cell 
response, it is associated with a number of cancers. One such malignancy is post-transplant 
lymphoproliferative disease (PTLD) that is susceptible to develop in immunosuppressed 
transplant patients. Recently, transfer of EBV specific T cells has been shown to be not only 
an effective treatment option for PTLD but also a highly successful prophylactic for patients 
at risk of developing this malady. Within this context it has been observed that a better 
clinical outcome is linked to a higher proportion of CD4+ T cells in the EBV specific 
preparations (Haque et al., 2007). Direct effector function of T cells has principally been 
associated with CD8+ T cells and the recognition of MHC class I expressing cells however it 
is now accepted that CD4+ T cells are also able to exert such functions on MHC class II 
positive cells. 
There is precedent for using CD4+ T cells in a therapeutic setting as a recent trial 
demonstrated that a melanoma patient achieved durable remission following infusion of a 
tumour antigen specific CD4+ T cell preparation (Hunder et al., 2008). Furthermore, a higher 
percentage of CD4+ T cells in EBV specific cytotoxic T cells administered for the treatment of 
PTLD is associated with a better clinical response (Haque et al., 2007). There is therefore 
potential for EBV specific CD4+ T cells to be use therapeutically for virus associated 
diseases. At present however, little is known about the functional characteristics of CD4+ T 
cells that control the persistent infection of the virus in healthy individuals. Understanding 
what types of T cells respond to EBV infected cells may be important in to help improve 
future therapies for not only PTLD but other cancers characterised by uncontrolled 
proliferation of MHC class II positive cells. 
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The recent advances in MHC class II tetramer technology has enabled the analysis of CD4+ 
T cells on a single cell basis and will allow further knowledge of CD4+ T cell function to be 
gained at the epitope level. 
Most studies analysing the ability of CD4+ T cells to directly recognise EBV infected cells 
have used in vitro isolated and expanded T cell clones. These have generally relied on 
assays that measure IFNγ (Amyes et al., 2003) however T cells producing IL-4 (Bickham et 
al., 2001) have also been observed. Such findings could however be artefacts of culturing T 
cell clones. In addition studies analysing the response of EBV specific CD4+ T cells ex vivo 
have been performed using overlapping peptide pools which do not necessarily correspond 
with the physiological amounts of antigen presented to T cells (Ning et al., 2011). The 
secretion of these cytokines has led to the categorisation of EBV specific CD4+ T cells into 
certain T helper cell subsets; however analysis of the expression of transcription factors in 
responding T cells has not yet been performed. Assessing the presence of transcription 
factors along with cytokines would enable the confirmation of the type of CD4+ T cell 
responding to EBV stimulus. It is also known that CD4+ T cells are a heterogeneous 
population and polyfunctional T cells secreting multiple cytokines are important in conferring 
T-cell immunity in human virus infections (Harari et al., 2006).  
We sought to gain a better understanding of EBV specific CD4+ T cells following activation by 
an EBV infected cell by analysing the expression of transcription factors and production of a 
range of cytokines. We successfully optimised a multitude of antibody panels that 
subsequently allowed us to measure the functional characteristics of interest.  
We therefore analysed the expression of transcription factors and cytokines associated with 
the Th1, Th2 and Treg CD4
+ T cell subsets following stimulation with autologous LCLs. In all of 
the panels tested here, we observed a CD4+ T cell response to autologous LCLs by secretion 
of IFNγ. The cells producing the anti-viral cytokine accounted for between 0.3 and 0.5% of 
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the total CD4+ population depending on the donor. This is in line with what is known about 
frequency of individual responses that range between 0.008 and 0.040% (Long et al. 2013) 
and the broad repertoire of epitopes recognised by CD4+ T cells (Long et al., 2011). 
Furthermore, a similar percentage of IFNγ producing CD4+ T cells within the total CD4+ 
populations was observed for a related herpesvirus, CMV (Gamadia et al., 2003). IFNγ is a 
cytokine predominantly associated with Th1 type T helper cells that express the transcription 
factor T-bet. Although cells responding to stimulation with EBV infected cells have been 
shown to produce IFNγ it was assumed that they were of a Th1 lineage without analysing 
expression of the associated transcription factor. With our antibody panels we were able to 
confirm this this by observing that approximately 90% of cells producing this cytokine also 
expressed the transcription factor T-bet. The high proportion of Th1 cells is to be expected as 
this subset is the host immunity effectors against intracellular viral pathogens. The secretion 
of IFNγ by this type of CD4+ T cell can activate phagocytic activity of macrophages and up 
regulates the expression of class I and II MHC functions to enhance the activity of cytotoxic T 
cells.  
Perhaps unsurprisingly we did not observe any CD4+ T cells positive for the Th2 associated 
transcription factor GATA3 producing IFNγ as this subset is associated with immune 
response to large extracellular pathogens. In contrast to previous studies we also did not 
observe any production of IL-4 in response to LCL stimulation. We did however detect a 
small percentage of cells expressing the Treg associated transcription factor FoxP3. 
Expression of cytokines more commonly associated with this subset such as IL-10 was not 
observed but studies have suggested that in a polarizing Th1 response regulatory T cells can 
be induced into producing IFNγ. In addition, such Th1-like Treg cells express the transcription 
factor T-bet alongside FoxP3 (Koch et al., 2009). In our experiments we did not seek to 
analyse the co-expression of T-bet and FoxP3, however given the dominant Th1 response 
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observed following LCL stimulation it would perhaps not be surprising to observe a 
suppressive subset directed against responding cells.   
Responses from un-manipulated CD4+ T cells were clearly seen in the circulating blood of all 
the healthy donors demonstrating that they are directly functional in short term assays 
against autologous LCLs (Long et al., 2005; Munz et al., 2000). Furthermore, responses 
were obtained with physiological level of naturally processed antigen present on the surface 
of virus infected cells as opposed to saturating concentrations of peptide pools (Ning et al., 
2011). These results suggest that circulating EBV specific CD4+ T cells may have similar 
direct function against virus infected B cells in vivo and thus are able to control infection. 
Our results show that CD4+ T cells responding ex vivo to autologous LCLs express the Th1 
associated transcription factor T-bet alongside IFNγ and TNFα predominantly as 
polyfunctional cells (Fig 3.2.b). However, we did not observe significant levels of IL-2 
production. This was unexpected as IL-2 can be used as a marker for T cell activation and 
stimulates the clonal expansion of CD8+ T cells while also stimulating proliferation of CD4+ T 
cells and has been detected in previous studies (Ning et al., 2011). This finding was 
nonetheless consistent throughout the donors and did not vary depending on the antibody 
used.  In addition we did not observe any cells responding to EBV infected cells by producing 
IL-4 as had been previously reported (Bickham et al., 2001). 
The assays analysing the CD4+ T cells following LCL stimulation have shown the profiles of 
the total EBV specific responses, however they do not give information regarding individual 
epitope specificities. The responses of CD8+ T cells to epitopes derived from lytic and latent 
antigens have been well studied and we therefore wanted to investigate profiles of EBV 
specific CD4+ T cells. To achieve this we took advantage of novel MHC class II tetramers to 
look for the first time at the responses at the epitope level.  We initially performed 
experiments with the EBNA2 derived peptide PRS (as the assay had previously been 
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optimised) before attempting to look at other CD4+ T cells specific for lytic and latent derived 
epitopes.  
Further examination of EBV specific CD4+ T cells using MHC class II tetramers revealed that 
cells specific for an epitope derived from the latent protein EBNA2 respond in a similar way 
to cells that have been stimulated by autologous LCLs. Indeed the majority of responding 
cells secreted IFNγ, TNFα, or both. Interestingly, there were background levels of TNFα 
observed in all donors but we did notice a dose dependent response when different dilutions 
of the tetramer were tested (data not shown) indicating that production of cytokines was not 
due to activation of the TCR upon binding of the MHC class II reagent as has been reported 
for MHC class I tetramers (. Furthermore, similar background levels were observed in the 
LCL stimulation experiments. 
Nevertheless it is important to note that not all cells positive for the cognate receptor to the 
PRS MHC class II tetramer responded to the peptide and produced cytokines. This further 
supports previous observations that even though these CD4+ T cells are evidently antigen 
experienced, they are capable of reverting to a central memory phenotype. Thus, not all 
EBV-specific cells are primed and immediately available as anti-viral effectors. In addition 
CD4+ T cells for a given epitope are likely to be a polyclonal population and therefore some 
may have low avidity TCR that were not activated by low concentrations of peptide. 
We intended to further confirm the functional characteristics observed with PRS specific 
CD4+ cells by analysing the profiles of CD4+ T cells directed against other lytic and latent 
protein derived antigens. However, multiple tests performed with increasing peptide 
concentrations and longer incubation times did not result in cells responding by producing 
IFNγ and TNFα as had previously been seen with the PRS peptide and therefore further 
optimisation is required. A potential alternative test would be to look at the CD4+ T cell 
response to LCLs pulsed with the peptide of interest. Indeed, EBV specific CD4+ T cell 
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clones have a higher capacity to directly recognise and kill LCLs when the target transformed 
cell line has been “primed” with peptides prior to incubation with the effector T cells (Long et 
al., 2005). 
Using MHC class II tetramer we were able to demonstrate that epitope specific CD4+ T cells 
can act as direct effectors ex vivo and we were interested in analysing whether this function 
was further extended to the ability to kill infected cells. Studies have shown that cytotoxic 
CD4+ T cells are present in low numbers in the circulating blood of healthy donors but are 
expanded in patients suffering from chronic viral infections such as HIV (Appay et al., 2002). 
They are characterised by the presence of perforin and display a distinct surface phenotype 
associated with end stage differentiation. Furthermore, it was observed that CD4+/perforin+ 
cells produced IFNγ and TNFα. Previous work performed with EBV specific CD4+ T cell 
clones has suggested that cytotoxic function is present (Long et al., 2005; Munz et al., 2000) 
however this may be an artefact of in vitro culture (Fleischer et al., 1984). Indeed,in vitro 
culture may drive CD4+ T cells  to  more differentiated phenotype  associated with cytotoxic 
capacity (Hintzen et al., 1993). 
By combining MHC class II staining along with perforin and granzyme staining we were able 
to analyse whether cells stained for the tetramer possessed cytotoxic potential. Additionally 
we included memory phenotype markers in order to assess the differentiation status of any 
cells that were positive for perforin or granzyme B.  
Within the the PRS tetramer specific population tested we did detect cells positive for 
perforin, granzyme B or a combination of both, however due to the small number of events 
analysed it was not possible to accurately determine the memory phenotype of these cells. 
The frequency of perforin and granzyme B expressing cells in the total CD4+ population was 
very low as has been previously reported (Appay et al., 2002). We did observe much higher 
levels of perforin and granzyme expressing CD4+ T cells in the total CD4+ T cell population in 
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one donor however we did not detect any tetramer positive cells with cytotoxic potential. Our 
initial tests suggest that EBV specific CD4+ T cells with cytotoxic potential are present at 
higher proportions in the blood of healthy donors. The repeated exposure of lymphocytes to 
EBV derived antigens in the circulating blood could increase the cytotoxic potential of EBV-
specific CD4+ T cells as has been seen in the context of other chronic viral infections such as 
HIV. 
The memory phenotype of the total tetramer positive population was similar to what had 
previously been seen despite using a distinct panel of antibodies and different donors (Long 
et al., 2013). The selection of the PRS tetramer may not have been the most appropriate for 
this assay as the response is low and using the SNP tetramer, which has a larger response 
in healthy donors, could have led to more events being analysed. These experiments do not 
require additional optimisation as peptide stimulation is not required and analysis was not 
performed due to time limitations. 
Presence of molecules associated with cytotoxicity does not necessarily result in cells killing 
when challenged with their cognate antigen. Thus, in addition to using flow cytometry 
analysis to assess cytotoxic potential we also performed one preliminary killing assay using a 
population of PRS specific CD4+ T cells enriched directly ex vivo. This purified population did 
appear to preferentially kill autologous LCLs pulsed with PRS peptide compared to an HLA 
mismatched LCL. Nonetheless cell numbers used in the assay were low and improving the 
yield and purity of PRS specific cells from donor PBMCs would be essential in order to 
confirm the initial observation. 
 
Overall, this study has shown for the first time that CD4+ T cells can have effector function 
directly ex vivo by responding to autologous LCLs by secreting the anti-viral cytokine IFNγ 
along with the inflammatory cytokine TNFα. We also confirmed that these cells were 
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predominantly of a Th1 subtype. Using MHC class II tetramers enabled us to analyse the 
responses at the epitope level and assays stimulating CD4+ T cells with an EBNA2 derived 
peptide also showed the majority of CD4+ T cells specific for the peptide expressed the Th1 
associated transcription factor T-bet. Furthermore, tetramer positive cells that responded to 
incubation with the peptide produced IFNγ and TNFα as was seen during stimulation with 
autologous LCLs. We also observed that unmanipulated CD4+ T cells analysed ex vivo 
possess cytotoxic potential and that such cells are specific for EBV derived antigens.  
Further work is however needed to analyse cytokine profiles across a range of epitopes from 
lytic and latent proteins. Moreover our initial observations that some EBV specific CD4+ T 
cells possess cytotoxic potential needs to be confirmed for other epitopes. Ultimately we 
would like to be able to set up a killing assay with enriched EBV specific CD4+ T cells to 
examine whether they are indeed able to kill EBV infected cells. 
The work performed here is important in the context of enhancing adoptive T cell therapies 
currently used for the EBV-related malignancy PTLD. By improving knowledge of the 
subtypes of CD4+ T cells responding to EBV in healthy donors, we will be able to 
preferentially stimulate those that can efficiently act directly on virus infected cells. Recently, 
peptide-selected T cells have been administered to patients suffering from 
lymphoproliferative diseases (Moosman et al., 2010; Icheva et al., 2013), and this approach 
could be further improved with knowledge of the CD4+ T cell epitopes that respond to 
antigenic stimulation in healthy donors.  
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